Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 32 entries
View as:

Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)

Phase: N/A Priority: Normal
NCT ID: NCT02383810 Org: User:
Start: 01/31/15 End: 02/29/16 Due: 02/28/17

Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea

Phase: N/A Priority: Normal
NCT ID: NCT01543451 Org: User:
Start: 02/29/12 End: 10/31/13 Due: 10/31/14

XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00090025 Org: User:
Start: 09/30/04 End: 11/30/06 Due: 11/30/07

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT03743064 Org: User:
Start: 05/06/19 End: 12/27/22 Due: 12/27/23

PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting

Phase: N/A Priority: Normal
NCT ID: NCT03204279 Org: User:
Start: 08/31/17 End: 09/30/19 Due: 09/30/20

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Phase: N/A Priority: Normal
NCT ID: NCT01376297 Org: User:
Start: 07/31/11 End: - Due: -

Oral Akynzeo® Vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

Phase: N/A Priority: Normal
NCT ID: NCT04817189 Org: User:
Start: 02/01/21 End: 07/02/24 Due: 07/02/25

Effects of Somnage® in the Management on Sleep and Mood in Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT02883790 Org: User:
Start: 10/31/15 End: 02/28/18 Due: 02/28/19

A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06840769 Org: User:
Start: 06/17/23 End: 10/23/23 Due: 10/23/24

Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02118909 Org: User:
Start: 05/31/14 End: 08/31/14 Due: 08/31/15

Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01887314 Org: User:
Start: 06/30/13 End: 10/31/15 Due: 10/31/16

Evaluation of the Effects of a Mixture of Amino Acids (Amixea) on Lean Body Mass and Muscle Strengh of Patients With Unresectable Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02877966 Org: User:
Start: 10/31/16 End: 12/31/18 Due: 12/31/19

Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)

Phase: N/A Priority: Normal
NCT ID: NCT06904235 Org: User:
Start: 04/28/25 End: 12/31/27 Due: 12/31/28

A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting

Phase: N/A Priority: Normal
NCT ID: NCT02517021 Org: User:
Start: 11/30/15 End: 08/31/16 Due: 08/31/17

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

Phase: N/A Priority: Normal
NCT ID: NCT01993641 Org: User:
Start: 12/31/13 End: 06/30/16 Due: 06/30/17

An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting

Phase: N/A Priority: Normal
NCT ID: NCT01363479 Org: User:
Start: 07/31/11 End: 11/30/12 Due: 11/30/13

Effects of Aqualief® in Patients With Xerostomia as Consequence of Radiotherapy for Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03601962 Org: User:
Start: 07/31/17 End: 01/22/20 Due: 01/22/21

A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The Body

Phase: N/A Priority: Normal
NCT ID: NCT03495934 Org: User:
Start: 02/08/18 End: 02/28/18 Due: 02/28/19

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Phase: N/A Priority: Normal
NCT ID: NCT05222165 Org: User:
Start: 10/01/21 End: 12/16/22 Due: 12/16/23

Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02058784 Org: User:
Start: 02/28/14 End: 03/31/14 Due: 03/31/15

Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

Phase: N/A Priority: Normal
NCT ID: NCT00828295 Org: User:
Start: 08/31/08 End: 01/31/09 Due: 01/31/10

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT03151304 Org: User:
Start: 06/01/17 End: 12/01/20 Due: 12/01/21

An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting

Phase: N/A Priority: Normal
NCT ID: NCT02557035 Org: User:
Start: 10/31/15 End: 03/31/16 Due: 03/31/17

Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

Phase: N/A Priority: Normal
NCT ID: NCT01442376 Org: User:
Start: 09/30/11 End: 11/30/12 Due: 11/30/13

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03403712 Org: User:
Start: 03/16/18 End: 09/19/18 Due: 09/19/19